Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Guvacine is a pyridine alkaloid found naturally in the Areca nut (Betel nut). It is an experimental small molecule drug with no approved medical indication. Guvacine acts as a selective inhibitor of GABA reuptake by binding to presynaptic GABA transporters (GATs), specifically inhibiting sodium- and chloride-dependent GABA transporter subtypes (GAT1/SLC6A1; GAT2/SLC6A13; GAT3/SLC6A11; BGT1/SLC6A12). This inhibition increases extracellular levels of gamma-Aminobutyric acid (GABA), the major inhibitory neurotransmitter in the mammalian brain. Notably, guvacine does not bind to or activate postsynaptic GABA receptors. Its main research interest lies in neuropharmacology and potential use for neuropsychiatric disorders[1][2][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on guvacine.